Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed, still-unnamed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital. The new company has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that ...